摘要
目的探讨分析替罗非班桥接双抗方案对超溶栓窗急性缺血性脑卒中(AIS)患者神经功能及预后的疗效。方法选取中国贵航集团三〇二医院2021年1月至2022年5月90例超溶栓窗急性缺血性脑卒中患者,随机分为两组,对照组给予双抗方案治疗,观察组在双抗方案基础上联合替罗非班治疗,比较两组患者临床疗效,治疗前、治疗24 h、14 d、90 d美国国立卫生研究院卒中量表(NIHSS)评分,治疗前、治疗后90 d改良Rankin量表评分(mRS)评分及并发症发生情况。结果观察组患者临床疗效总有效率为88.89%,高于对照组患者(80.00%)(P<0.05)。治疗前两组患者NIHSS评分差异无统计学意义(P>0.05),治疗后24 h、14 d、90 d观察组NIHSS评分低于对照组(P<0.05)。治疗前两组mRS评分差异无统计学意义(P>0.05),治疗后90 d观察组mRS评分低于对照组(P<0.05)。观察组并发症发生率低于对照组(P<0.05)。结论替罗非班桥接双抗方案治疗超溶栓时间窗AIS患者可提高临床疗效,促进神经功能恢复,改善预后,提高治疗的安全性,值得推广。
【Objective】To investigate and analyze the efficacy of tirofiban bridging double-antibody regimen on the neurological function and prognosis of patients with acute ischemic stroke in the ultra-thrombolytic window.【Methods】Ninety ultra-thrombolytic patients who were treated from January 2021 to May 2022 were selected.The patients with acute ischemic stroke in the embolization window were randomly divided into the observation group and the control group.The control group was only given the dual antibody regimen,and the observation group was combined with tirofiban.The clinical efficacy of the two groups of patients was compared.NIHSS score before treatment,24h,14d,90d after treatment,mRS score before treatment and 90d after treatment,and the incidence of complications between the two groups were compared.【Results】The total effective rate of clinical efficacy in the observation group(88.89%)was significantly higher than that in the control group(80.00%)(P<0.05).There was no significant difference in NIHSS scores between the two groups before treatment(P>0.05),the NIHSS scores of the two groups were significantly decreased at 24h,14d,and 90d after treatment,and the NIHSS scores of the observation group were significantly lower than those of the control group at 24h,14d,and 90d after treatment(P<0.05).There was no significant difference in mRS scores between the two groups before treatment(P>0.05),and 90 days after treatment,the mRS scores of the two groups were significantly decreased,and the mRS scores of the observation group were significantly lower than those of the control group at 90 days after treatment(P<0.05).The incidence of complications in the observation group was significantly lower than that in the control group(P<0.05).【Conclusion】The tirofiban bridging double-antibody regimen in the treatment of patients with AIS beyond the thrombolysis time window can improve the clinical efficacy and promote the recovery of nerve function,improve prognosis,enhance the safety of treatment,which is worthy of promotion.
作者
覃玉术
黄述春
刘银银
吕正祥
QIN Yushu;HUANG Shuchun;LIU Yinyin;LYU Zhengxiang(Hospital 302 Attached to Guizhou Aviation Group,Anshun,Guizhou 561000,China)
出处
《中国医学工程》
2023年第5期91-94,共4页
China Medical Engineering
基金
安顺市科技计划项目[安市科社(2021)61号]。
关键词
替罗非班
双抗方案
超溶栓时间窗
急性缺血性脑卒中
神经功能
tirofiban
dual-antibody regimen
ultra-thrombolytic time window
acute ischemic stroke
neurological function
